Search

Zentalis Pharmaceuticals Inc

Slēgts

4.57 2.01

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.11

Max

4.67

Galvenie mērījumi

By Trading Economics

Ienākumi

-136K

-35M

EPS

-0.503

Darbinieki

106

EBITDA

2.2M

-35M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+61.64% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 4. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

26M

321M

Iepriekšējā atvēršanas cena

2.56

Iepriekšējā slēgšanas cena

4.57

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 28. jūl. 23:56 UTC

Correlated Moves

Shares of T Rowe Price Group Inc declined in after-market trading, reversing a trend of higher closes over the previous three sessions.

2026. g. 28. jūl. 23:56 UTC

Krispy Kreme Inc shares are higher in after-market hours, reflecting broader market gains driven by strong earnings from Coca-Cola and UPS.

2026. g. 28. jūl. 23:56 UTC

Northern Trust Corp shares are trading lower in after-market hours, remaining below their 20-day moving average and near the lower end of their one-month range.

2026. g. 28. jūl. 23:56 UTC

Yelp Inc shares are higher in after-market hours, continuing a recent upward trend amid broader market gains driven by strong earnings from Coca-Cola and UPS.

2026. g. 28. jūl. 23:56 UTC

Correlated Moves

ProPetro Holding Corp shares rose during after-market hours, aligning with a 3.61% increase in the VanEck Oil Services ETF amid positive sector sentiment.

2026. g. 28. jūl. 23:56 UTC

Correlated Moves

Encore Capital Group shares rose in after-market hours, reflecting positive market sentiment. The Russell 2000 Index also increased, supporting investor confidence.

2026. g. 28. jūl. 23:56 UTC

Immunovant Inc shares higher in after-market trading, reflecting broader market strength amid positive earnings from companies like UPS and Coca-Cola.

2026. g. 28. jūl. 23:56 UTC

Palo Alto Networks shares rose in after-market trading, supported by broader market gains and strong earnings from companies like Coca-Cola and UPS.

2026. g. 28. jūl. 23:56 UTC

Carvana Co shares are lower in after-market trading, with no specific news identified to explain the decline. The stock reversed from earlier gains.

2026. g. 28. jūl. 23:56 UTC

Rollins Inc. shares rose slightly in after-market trading, with no specific news identified. Broader market gains were supported by strong earnings from UPS and Coca-Cola.

2026. g. 28. jūl. 23:56 UTC

Viasat Inc. shares rose in after-market trading, reflecting broader market strength from positive earnings reports, including those from Coca-Cola and UPS.

2026. g. 28. jūl. 23:56 UTC

News

Coursera Inc announced a $100 million investment in LearnVector, enhancing its AI strategy. Shares are trading higher during after-market hours.

2026. g. 28. jūl. 23:56 UTC

Correlated Moves

Pentair PLC's shares were roughly flat in after-market hours amid broader market gains driven by strong earnings from Coca-Cola and UPS.

2026. g. 28. jūl. 23:56 UTC

Iovance Biotherapeutics shares declined in after-market trading, continuing a trend of lower finishes over the past five sessions. No specific news was identified.

2026. g. 28. jūl. 23:56 UTC

Microchip Technology Inc shares are lower in after-market trading, continuing a six-session decline amid a broader market rally driven by strong earnings from UPS.

2026. g. 28. jūl. 23:56 UTC

Correlated Moves

Vishay Intertechnology shares are lower in after-hours trading, continuing a decline seen since Tuesday. The stock remains below its 20-day moving average.

2026. g. 28. jūl. 23:56 UTC

Viavi Solutions Inc shares are lower in after-market trading. No specific news was identified to explain the decline amid broader market gains.

2026. g. 28. jūl. 23:56 UTC

Arista Networks Inc shares are lower in after-market hours. No specific news was identified for the decline, which follows three consecutive sessions of losses.

2026. g. 28. jūl. 23:56 UTC

Geo Group Inc shares are higher in after-market hours, supported by broader market strength from strong earnings reports, including those from UPS and Coca-Cola.

2026. g. 28. jūl. 23:56 UTC

Borgwarner Inc shares are higher in after-market trading, rebounding from an earlier dip amid broader market gains driven by strong earnings from UPS and Coca-Cola.

2026. g. 28. jūl. 23:52 UTC

News
Correlated Moves
Social Media

Apple Inc. shares are higher in after-market trading as the company surpasses a $5 trillion market capitalization ahead of its Q3 earnings report.

2026. g. 28. jūl. 23:52 UTC

OUTFRONT Media Inc shares are lower in after-market trading, declining since Tuesday's close despite three consecutive sessions of gains. No specific news was identified.

2026. g. 28. jūl. 23:52 UTC

Mexican Consumer Confidence Index Set for Release Amid Global Mixed Signals and Local Pessimism, Anticipated to Reflect Economic Sentiment on August 4, 2026.

2026. g. 28. jūl. 23:52 UTC

Brazil's Industrial Production MoM data for June 2026 set to release on August 4, amid cautious market sentiment following May's unexpected decline.

2026. g. 28. jūl. 23:52 UTC

Brazil's Central Bank Faces Mixed Market Sentiment Ahead of August 2026 Interest Rate Decision Amid Inflation and Economic Concerns.

2026. g. 28. jūl. 23:52 UTC

Australia's Producer Price Inflation (PPI) set for July 31, with a projected 0.3% increase amid cautious inflation sentiment and potential interest rate hikes from the Reserve Bank of Australia.

2026. g. 28. jūl. 23:52 UTC

South Korea's S&P Global Manufacturing PMI set for August 3, with expectations of declining activity amid rising costs and significant stock market drops.

2026. g. 28. jūl. 23:52 UTC

China's Non-Manufacturing PMI set for July 31 release, forecasted at neutral 50.0 amid mixed economic sentiment and geopolitical tensions.

2026. g. 28. jūl. 23:52 UTC

China's NBS Manufacturing PMI forecasted to hold steady at 50.0, signaling stagnation amid mixed global manufacturing signals ahead of July 31st release.

2026. g. 28. jūl. 23:52 UTC

Social Media
News

Avis Budget Group shares lower in after-market trading following second-quarter results that missed expectations, with EPS of $0.98 against estimates of $1.91.

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

61.64% augšup

Prognoze 12 mēnešiem

Vidējais 7.29 USD  61.64%

Augstākais 11 USD

Zemākais 4 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

8 ratings

5

Pirkt

3

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat